Drugs / DESF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06527937 | Jul → Oct 2024 | hypersensitivity reaction disease | Aquestive Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DESF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06527937 ↗ |
| Route | Other | “DESF administered in the sublingual space.” NCT06527937 ↗ |